Filed in archive
Drugs, Vaccines and Therapeutics
, Gene Therapy
, Nanomedicine
by ruth on April 24, 2007
A preliminary clinical trial has demonstrated that an intravenuously administered nanoparticle containing the FUS1 gene shows clinical activity in stage 4 Lung Cancer Patients. FUS1 can induce apoptosis - programmed cell death - in cancer cells but is absent in those cells.The nanoparticle delivery system consists of a plasmid gene expression cassette loaded with DNA that encodes the FUS1 protein. This is wrapped tightly in a form of cholesterol to protect it from the body's defense mechanisms. The nanoparticles accumulate mainly in the lungs, particularly in the tumors, where the genes repeatedly express FUS1 tumor-suppressing proteins.
In the study, the median survival time for all patients is 14.6 months, which is considerably longer than the seven-month median survival time for patients receiving second line therapy. More details from the MD Anderson Cancer Center.
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/65205
Addthis
Ask
Blinklist
del.icio.us
Digg
Fark
Facebook
Google
Lycos
Ma.gnolia
Mr Wong
Netscape
Netvousz
Newsvine
Reddit
StumbleUpon
Slashdot
Tailrank
Technorati
Wink
Yahoo
Vote for Nanotechnology and Gene Therapy Against Stage IV Lung Cancer:
|
Rating: 9.50 out of 4 vote(s) cast.
|
Subscribe
Use the search to look for other interesting posts
| RSS |  See all blog subscribe options |
 What is RSS? | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
| Newsletter | |
| Follow us on Twitter! |
